Public reporting burden for this collection of information is estimated to average 1 hour per response, including (he lime for reviewing instructions, searching existing data sources, gathering and maintain™ the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services. Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302 and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503 
INTRODUCTION
As described and approved in the last report, Task 2 of the project has been modified to facilitate the translation of the lab products to potential clinical trials. Therefore, Flu peptide MP-58 GILGFVFTL presented by human HLA-A2.1 rather than beta-galatosidase peptide TPHPARIGL presented by mouse K d is used for pro-peptide development. In this report, Task 3 is modified in order to measure MP-58 prodrug activity with human effector cells in vitro. The specific Tasks are :
Task 1 Establish an in vitro assay to measure tumor growth inhibition by peptide specific T cells and pro-peptides Task 2 Synthesize and test the activity of pro-peptides to be activated by ß-glucuronidase at the tumor site (A) Synthesis of glucuronide derivatives of Flu peptide MP-58 GILGFVFTL presented by humanHLA-A2.1. (B) Measurement of peptide and pro-peptide binding to MHC. Task 3 Develop human anti-MP58 CTL line and measure pro-peptide activity with anti-MP58 CTL.
BODY Task 1 Establish an in vitro assay to measure tumor growth inhibition by peptide specific T cells and pro-peptides
Results from this task were detailed in previous progress reports. A paper describing this task has been published (Appendix A).
Task 2
Synthesize and test the activity of pro-peptides to be activated by ß-glucuronidase at the tumor site (A) Synthesis of glucuronide derivatives of Flu peptide MP-58 GILGFVFTL presented by human HLA-A2.1. (B) Measurement of peptide and pro-peptide binding to MHC. Results from this task have been published (Appendix B).
Two methods for synthesis of prodrugs of MP58 2a (see appendix B) activated by betaglucuronidase and comprising a self-immolative 3-nitrobenzyloxycarbonyl moiety were investigated. Reaction of beta-glucuronic acid glycoside of 4-hydroxy-3-nitrobenzyl alcohol (3) with N,N'-disuccinimidyl carbonate (DSC) followed by conjugation with AlaOme, Gly, Thr, Phe-Leu, or Leu-Arg gave carbamates 4a-4f. Deacetylation of 4b and 4e with MeONa/MeOH gave beta-glucuronides 5b and 5e. Compound 5e was converted to beta-glucuronic acid conjugate 6e by the action of pig liver esterase (PLE). Compound 6e is a substrate for betaglucuronidase. Method of a direct introduction of the prodrug residue into MP58 GILGFVFTL (2b) failed. Alternately, glycine conjugate 5b was activated to pentafluorophenyl ester 10. Model coupling of 10 with Phe-Leu gave tripeptide conjugate ester 1 la which was hydrolyzed by PLE to uronic acid 12. Condensation of 10 with octapeptide ILGFVFTL (9) gave prodrug precursor lib. Octapeptide 9 was prepared by de novo synthesis using a racemization -free
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stricted immunogenic peptides can induce tumor antigen-specific immunity. BALB/c mammary tumor growth was inhibited in mice immunized with peptide E474 from the envelope protein of mouse mammary tumor virus (MMTV) (Wei et al., 1996a,b) . HLA-A1-associated MAGE-3 peptide induced tumor shrinkage in three of sixteen melanoma patients (Marchand et al., 1995) . Immunization with HLA-A2-restricted gplOO peptide combined with systemic IL-2 treatment induced partial response in 42% of melanoma patients (Rosenberg et al., 1998) . Patients with metastatic melanoma showed complete 0022-1759/01/$ -see front matter ©2001 Elsevier Science B.V. All rights reserved. PIT: S0022-1759(01)00484-7 response after they were immunized with dendritic cells loaded with three melanoma peptides (Nestle et al, 1998) . These examples indicated the anti-tumor efficacy of peptide-specific cytotoxic T cells (CTL). Several limitations in tumor-specific immunotherapy prompted us to search for alternative approaches. Antigen expression by tumor cells is heterogeneous and T cells recognizing tumor-specific antigens may eliminate antigen positive tumor cells, but allow the expansion of antigen negative cells. A limited number of tumor-associated antigens have been identified and many of them are weak antigens (Pardoll, 1998) . When immunity to tumor-associated self antigens is successfully induced, autoimmunity becomes a risk factor. An alternative approach to exploit effector T cells without being limited by the tumor-associated antigens will be of great advantage.
Chemotherapeutic agents can be delivered to the tumors under the cover of pro-drugs. A nontoxic glucuronyl-spacer-doxorubicin prodrug HMR 1826 was activated selectively by ß-glucuronidase which is found at high concentration at the tumor site (Murdter et al, 1997; . Treatment with HMR 1826 resulted in tumor destruction without systemic toxicity. The findings with HMR 1826 encouraged the strategy of delivering antigenic peptides under the cover of pro-peptides. A propeptide can be synthesized by conjugating glucuronide to the amino terminus through the self-immolative linker (Rawale et al, 2001 ). The pro-peptide does not bind to MHC class I antigen, but ß-glucuronidase can cleave and release the active peptide, which then binds to MHC class I antigen. The current study is undertaken to establish the in vitro and in vivo assay methods for measuring anti-tumor activity of CTL to foreign peptides.
Therapeutic potential of CTL against a solid tumor was first demonstrated in vitro in collagen gel (Wei et al., 1985 (Wei et al., , 1996a . Tumor cells grew as a 3-D mass with intracellular junctions and resembled a solid tumor. The tumor mass could be maintained in the collagen gel for 1-2 weeks, providing prolonged observation period and a realistic in vitro system to measure anti-tumor activity (Gavin et al., 1993) . Activated T cells migrated through the collagen gel (Ratner et al., 1992) and inhibition of tumor growth was monitored by daily measurement of the tumor size.
To sustain CTL activity in vivo, CD4 T cells were activated by Pan DR reactive epitope (PADRE) aK(X)VAAWTLKAAa (a is D-alanine and X is cyclohexylalanine), a synthetic peptide containing amino acid sequences derived from the circumsporozoite protein (CSP) from Plasmodium falciparum. PADRE binds multiple LHA-DR allospecificity and murine I-A b/d or I-E b/d antigens (Alexander et al., 1994) and induces helper T cell activity. The efficacy of PADRE to enhance anti-tumor CTL activity was examined.
Materials and methods

Mice and cell lines
BALB/c mice originally obtained from the Cancer Research Laboratory, Berkeley, CA were bred by brother-sister mating in our animal care facility. The use and care of experimental mice are in accordance with the guidelines of Wayne State University Animal Investigation Committee. Mouse mammary tumor cell line D2F2 was cloned from a spontaneous mammary tumor, which arose in a BALB/c hyperplastic alveolar nodule line D2 (Mahoney et al., 1985) . MMT cell line 168 was cloned from a spontaneous tumor in a BALB/cfC3H mouse which was the offspring of BALB/c mice foster nursed on C3H/HeJ mothers infected with MMTV(C3H) (Wei et al., 1993) . Cell line 293 (American Type Culture Collection, Manassas, VA) is a human embryonic kidney cell line transformed with Ad5 El A and E1B genes, and supports the propagation of El deleted recombinant adenovirus. All tissue culture reagents were obtained from GIBCO Laboratories (Grand Island, NY) unless otherwise specified. The cell lines were maintained in Dulbecco's modified Eagle's medium (DME) supplemented with 5% heat-inactivated fetal calf serum (HyClone, Logan, UT), 10% NCTC 109 medium (Sigma, St. Louis, MO), 8 p,g/ml bovine crystalline insulin (Sigma), 1 mM oxalacetic acid, 0.5 mM sodium pyruvate, 2 mM L-glutamate, 0.1 mM MEM nonessential amino acids, 100 units/ml penicillin and 100 |Jig/ml streptomycin.
Peptides
Beta-galactosidase (ß-gal) peptide p876 TPH-PARIGL and PADRE aK(X)VAAWTLKAAa (a is D-alanine and X is cyclohexylalanine) were synthesized at Genemed Synthesis (South San Francisco, CA).
Establishment of peptide-specifw CTL
BALB/c mice were injected s.c. at the tail base with 100 (jug of p876 emulsified in 0.1 ml of 50% complete Freund's adjuvant (CFA). At 10 days after the injection, the spleen and lymph nodes were aseptically removed from immunized mice and a single-cell suspension was prepared. The freshly isolated cells were cultured with peptide-loaded, irradiated splenocytes in 12-well plates in RPMI 1640 medium containing 50 |xM of 2-mercaptoethanol, 10% fetal calf serum, 5% mixed leukocyte culture supernatant and 18 IU/ml of recombinant hIL-2 (Cetus, Emeryville, CA). The ratio of stimulators to responders was 2:1.
To prepare the stimulators, autologous splenocytes were incubated with 100 |xg/ml of p876 for 2 h, exposed to 1000 rad irradiation from a Cesium irradiator and washed to remove excess peptides before they were added to the culture. The cultured cells were re-stimulated with peptide-loaded splenocytes every 7-10 days.
Mixed leukocyte culture was prepared by incubating BALB/c splenocytes with irradiated human peripheral blood leukocytes for 48 h in RPMI 1640 medium with 10% FCS. The ratio of mouse and human cells was 1:1 and the total cell concentration was 5 X 10 6 cells/ml.
5, Cr release assay
D2F2 tumor target cells were labeled by incubating 10 X 10 6 cells with 100 |x Ci Na 51 Cr0 4 (NEN Research Products, Boston, MA) in 1 ml of complete DME at 37 °C for 2 h. In some experiments, the target cells were loaded with p876 peptide by adding 100 |xg of p876 during the incubation. The unincorporated 5l Cr and unbound peptide was removed by three washes with Hanks' balanced salt solution containing 2% calf serum and 2 mM Hepes buffer.
Graded numbers of effector cells were mixed with 1 X 10 5 labeled target cells in 200 |xl of DME in the wells of round bottom microtiter plates. After centrifugation at 200 X g for 1 min, the plate was incubated at 37 °C for 4.5 h. After the incubation, the plate was centrifuged at 480 X g for 10 min and a 100-(xl aliquot was removed from each well for counting in the gamma counter. The percent lysis was calculated as follows % specific lysis = 100 X (cpm lcst -cpm mcdium ) /(cpm max -cpm mcdium ).
The cpm max was determined by adding 1/6 N HCL to wells containing 5l Cr-labeled target cells. Each group contained four replicates.
A 3-D collagen gel assay
The growth and lysis of tumor cell boluses in the collagen were previously reported (Wei et al., 1996a,b) and are briefly described here. Collagen stock solution was prepared from rat tail tendons. The complete collagen mixture contained 12 parts of cold collagen stock, 2 parts of 7.5 X RPMI 1640 medium, 0.6 parts of 7.5% sodium bicarbonate and 0.5 parts of 0.34 N NaOH. This mixture stayed in liquid form if kept on ice. Tumor cell boluses were prepared by suspending 1 X 10 5 tumor cells with or without CTL in 1 |xl of complete collagen mixture and embedded between two layers of collagen gels. The gel was bathed in RPMI 1640 medium supplemented with 50 |JLM of 2-mercaptoethanol, 10% fetal calf serum, 5% mixed leukocyte culture supernatant and 18 IU/ml of recombinant hIL-2 (Cetus). Tumor cells established inter-cellular junction and formed a cell mass during overnight culture (Wei et al., 1985 (Wei et al., , 1996a . In some experiments, the CTL were added to the top of the collagen and allowed to migrate into the gel. Peptide p876 was added the day after CTL were embedded or added. The plates were incubated at 37 °C and tumor growth was measured every other day.
Tumor cell boluses embedded in collagen gel were examined with an inverted micropscope equipped with a split image tracing device, using 1 X objective. The projected image of the cell bolus 144 W.-Z. Wei et al./ Journal ofImmunological Methods 258 (2001) [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] was traced and the surface area was calculated. The result was expressed as the square root of the measured area, which represented the mean diameter of the bolus, multiplied by a constant. The difference between the test and control group was determined with one-tail Student's Mest. There were four replicates in each group.
Foot pad swelling test
BALB/c female mice were immunized by s.c. injection with 20 jxg of PADRE and 100 jxg of p876 in 50% IFA, and challenged 2 weeks later in the foot pads with either or both peptides in 20 \i\ of saline. The thickness of the feet was measured with a caliper at 24 and 48 h after injection. The significance of the swelling was determined by comparing each test group with the saline control group using Student's Mest. There were seven to eight mice in each group.
Lymphocyte proliferation assay
Lymph nodes were removed aseptically from mice, and a single-cell suspension was prepared in RPMI 1640 medium supplemented with 4% fetal calf serum. Suspended cells were distributed to round bottom wells of a 96-well plate and each well received 1.5 X 10 5 cells. Test peptide at varying concentrations or Concanavalin A (con A) at 1 |xg/ml was added to each well. There were four replicates in each group. Cells were incubated in 5% C0 2 at 37 °C for 4 days. Each well received 1 \L mCi of 3 H-thymidine, and the cells were further incubated for 4 h before they were harvested with Harvester96 (Tomtec, Hamden, CT), and the incorporated 3 H was counted with TRILUX liquid scintillation and luminescence counter (Wallac, Turku, Finland).
Preparation of AdCMVLacZ
The construction of AdCMVLacZ was previously reported (Acsadi et al., 1994) . The recombinant virus was purified through two rounds of plaque purification, propagated in 293 cells, and isolated on a discontinuous cesium chloride gradient. The virus was collected and the salt was removed with a Sephadex column. The quantity of viral particles was estimated by measuring the optical density at 260 nm and the plaque-forming unit (PFU) was determined by direct plaque assay with 293 cells.
Tumor growth inhibition assay
Female BALB/c mice at 6 weeks of age were immunized by intracutaneous injection with 0.1 ml of saline containing 1 X 10 10 PFU of AdCMVLacZ, and boosted, 2 weeks later, by s.c. injection at the tail base with 0.1 ml of 50% IFA containing 100 |xg of p876 and/or 20 |xg of PADRE. At 2 weeks after vaccination, mice were injected s.c. on the flank with 1 X 10 5 untreated or peptide-coated D2F2 cells. Starting the day after tumor cell challenge, mice received subcutaneously, every other day, at the tumor site, 0.1 ml of saline containing 100 (xg of p876 and/or 40 p,g PADRE. A total of five injections were administered and tumor growth was monitored weekly. There were eight mice in each group.
Results
Inhibition of tumor growth by p876-specific CTL in vitro
BALB/c CTL to ß-gal peptide p876 was established as described in Materials and methods. After the fifth in vitro stimulation, more than 99% of the cells were CD8 + (not shown). CTL were frozen between the seventh and tenth stimulation and they were readily reactivated. The specificity was measured by the 51 Cr release assay. CTL lysed peptide p876-coated BALB/c mouse mammary tumor D2F2 cells, but not untreated D2F2 cells (Fig. 1) . Expression of L d by D2F2 cells was verified by flow cytometry (not shown).
The activity of p876-specific CTL against a solid tumor was tested in a 3-D collagen gel to access peptide loading and CTL lysis of a tumor mass. A total of 1 X 10 5 D2F2 cells and 3 X 10 5 CTL were embedded together in 1 \xA of collagen (Fig. IB) . After an overnight incubation when the cell bolus was established, p876 at 5 or 20 |xg/ml was added to the culture and tumor growth was monitored for 7 5 D2F2 cells were co-embedded with 3 X 10 5 anti-p876 CTL in 1 pJ of collagen. After an overnight incubation at 37 °C, p876 at 5 (solid square) or 20 (open triangle) u,g/ml was added to the culture. Control group (solid circle) did not receive peptide. Alternatively, 1 X 10 5 D2F2 (C) or 168 (D) cells were embedded alone in 1 u,l of collagen, and 3 X 10 anti-p876 CTL were added to the collagen gel after a tumor mass is established overnight. CTL migrated through the gel and p876 peptide was added after 24 h. Tumor growth was measured by the square root of the growth area. * indicates significant difference between the control and test groups at P < 0. 005. days. Without exogenous p876, D2F2 cells, co-embedded with anti-p876 CTL, grew progressively. The addition of p876 resulted in profound inhibition of tumor growth. Therefore, tumor cells in the solid mass were loaded with the exogenous peptide and are targets of CTL lysis.
Anti-tumor activity was further tested by embedding D2F2 cells in the collagen to establish a tumor mass before CTL and peptides were added. Therefore, 1 X 10 5 D2F2 cells were embedded and incubated overnight to establish a tumor mass with intercellular junctions (Fig. 1C) . CTL were added to the top of the gel and approximately 20-40% of CTL migrated through the collagen in 18 h (Ratner et al., 1992) when peptide p876 at 5 or 20 |xg/ml was added. Complete disintegration of the tumor boluses was observed after 5 days of culture. Vigorous proliferation of CTL was observed in and around the tumor (not shown). The destruction of tumor cell boluses was verified with another mouse ■ 1 wk □ 2wk
M3wk ^4wk
D2F2 loaded with saline P876 p876 p876
Treatment none none p876 saline Fig. 2 . D2F2 tumor growth in p876-immunized and treated mice. BALB/c mice were immunized i.e. with 1 X 10 10 PFU of AdCMVLacZ and boosted with ß-gal p876. At 2 weeks after vaccination, each mouse received s.c, 1 X 10 5 D2F2 cells coated or not-coated with ß-gal p876. Mice injected with peptide-coated cells received peri-lesional injection of 200 (j,g p876 in 100 JJLI of saline every other day, five times, starting the day after tumor cell injection. Control mice received saline injection or were not treated. mammary tumor cell line 168, which also expressed L d antigen (Fig. ID) . The extended culture period of the tumor boluses will be a particular advantage for testing pro-peptides, which are released by tumor-associated enzymes.
Effect of p876 on tumor growth in BALB/c mice
To test anti-tumor activity of p876-specific CTL in vivo, BALB/c mice were immunized with AdCMVLacZ to activate ß-gal specific CTL and boosted in 2 weeks with 100 |xg p876 in IFA. At 2 weeks after peptide immunization, mice were challenged with D2F2 cells pre-coated with p876. Starting the day after tumor cell challenge, mice were injected at the tumor site, every other day, with 200 p,g of p876 in 0.1 ml saline. There were five injections in 10 days. Control mice received saline or were not treated. One group received uncoated D2F2 cells. There was no demonstrable protection in any of the treatment group (Fig. 2) . We previously showed that immunization with irrelevant peptides had no effect on tumor growth (Wei et al., 1996a,b) . The inability to inhibit tumor growth by local administration of p876 may be due to inadequate number of CTL at the tumor site as a result of inadequate cytokine or accessory signals. In the 3-D collagen, exogenous IL-2 was required to achieve complete tumor destruction, indicating that continued stimulation and expansion of the CTL was necessary for controlling tumor growth (Wei et al., 1996a,b) .
T cell activation by PADRE
To enhance local recruitment or maintenance of CTL, CD4 T cell reactive peptide was incorporated Mice were immunized and challenged as described in Materials and methods. There were eight mice in each group. * P value was determined by the Student's f-test.
into the treatment regimen. PADRE, which binds to a wide range of human and murine MHC class II antigen, was tested as local CD4 T cell activator.
The immunogenicity of PADRE was tested by the foot pad swelling assay. BALB/c mice were immunized s.c. with 20 (xg of PADRE in 0.1 ml of 50% CFA and challenged 2 weeks later in the foot pad with 40 ug of PADRE in 20 ul of saline. Significant swelling was induced by PADRE both 1 and 2 days after challenge (Table 1) . Injection of PADRE in control mice or injection of saline in PADRE-immunized mice did not induce significant swelling. Therefore, PADRE-specific T cells were activated in vivo by peptide immunization. Delayed-type hypersensitivity, induced by a combination of p876 and PADRE, was also tested. Mice were immunized with 100 ug of p876 and 20 jxg of PADRE in Incomplete Freund's adjuvant and challenged 2 weeks later with p876, PADRE or a mixture of both peptides. Significant increase in foot pad thickness was observed after PADRE was injected ( Table 2) . Injection of both p876 and PADRE further enhanced the immune reactivity. p876 alone did not have significant effect. These results support the immunogenicity of PADRE in BALB/c mice and an enhanced inflammatory reaction when both MHC class I and II antigen reactive peptides were present. Activation of T cells was also measured by lymphocyte proliferation assay (Table 3) . Lymph node cells were prepared from BALB/c mice 2 weeks after mice were immunized s.c. with 20 \ig of PADRE in 0.1 ml of 50% CFA. Immune cells were incubated with 0.1-10 |xg of PADRE and 3 Hthymidine incorporation was measured after 4 days of culture. Incorporation of 3 H-thymidine was increased by more than 100 fold in sensitized lymphocytes when incubated with 10 ixg of PADRE. Naive lymphocytes did not demonstrate significant activity, supporting specific immune activation by PADRE.
Anti-tumor activity ofp876 and PADRE
To test the therapeutic effect of p876 and PADRE, BALB/c mice were immunized with AdCMVLacZ and boosted in 2 weeks with 100 (xg p876 and 20 ixg PADRE in IFA. At 2 weeks after the second immunization, mice received s.c. D2F2 cells precoated with p876 and mixed with PADRE. Mice were treated five times at the tumor site with a mixture of PADRE and p876, every other day. Complete inhibition of D2F2 tumor growth was observed in mice treated with PADRE and p876 (Fig. 3) . Immunization and treatment with PADRE alone had a minor anti-tumor activity (not shown). These re- suits demonstrated that activation of both CD4 and CD8 T cells at the tumor site with foreign peptide eliminated tumors loaded with the specific peptides.
Discussion
This study outlines a scheme for inducing and measuring anti-tumor activity mediated by T cells to foreign peptides. CTL to ß-gal peptide p876 eliminated tumor boluses in a 3-D matrix, demonstrating effective loading of p876 in a solid mass, migration of CTL to the tumor and sustained CTL killing at the tumor site. Exogenous IL-2 was necessary to maintain CTL activity. In vivo, tumors were rejected if they were loaded with p876 and PADRE and treated locally with the same peptides. PADRE was required to sustain CTL activity in vivo. Although tumor cells were loaded with peptides in this study, it should be possible to deliver foreign peptides onto tumor cells in vivo by appropriate vehicles. The pro-peptide developed by our group does not bind MHC class I antigen until the active peptide is released by betaglucuronidase (Rawale et al., 2001 ID: 2226 . Based on the same principle, doxorubicin prodrug HMR 1826 was activated selectively at the tumor site by ß-glucuronidase and demonstrated anti-tumor activity without systemic toxicity (Murdter et al., 1997; . It is anticipated that pro-peptide can be delivered to the tumors by systemic administration. The 3-D tumor growth assay and in vivo tumor inhibition in the presence of PADRE will be useful for testing pro-peptides and other derivatives of MHC class I antigen-associated peptides.
ß-gal encoded by Escherichia coli lacZ gene is widely used as a genetic tracer. It is immunogenic and L d -restricted epitope p876 TPHPARIGL was previously defined (Rammensee et al., 1989; Gavin et al., 1993) . Immunization of BALB/c mice with p876 inhibited the growth of a colon carcinoma genetically engineered to express ß-gal, supporting the cytotoxic activity of anti-ß-gal CTL (Specht et al., 1997) . Here, we showed that p876 effectively marked a solid tumor when loaded exogenously onto the tumor cells.
Tumor growth in the 3-D collagen gel is a useful indicator of CTL activity against solid tumors. When CTL were co-embedded with the tumor cells, tumor growth was inhibited, but some tumor cells remained after 2 weeks (not shown). When the same number of CTL were added exogenously, less than half migrated through the gel. These migratory T cells caused complete disintegration of the tumor. When CTL were packed in close proximity in the cell bolus, they may recognize neighboring CTL loaded with p876 and lyse each other. Alternatively, tumor cells may demonstrate immune suppressive activity, e.g. Fas ligand on tumor cells may induce T cell apoptosis. (Whiteside and Rabinowich, 1998; Sarma et al., 1992; Zeytun et al., 1997) . These mechanisms can significantly reduce the number of functional effectors in the tumor mass. T cells present in human tumors may be similarly ineffective because of the hostile microenvironment. When the hosts are immunized with foreign peptides, peptide-specific T cells will reside in the peripheral lymphoid organs until they are recruited to the tumor site by the injected peptides. When recruited to the tumor from the periphery, they may be more efficacious than resident T cells against tumor cells.
The in vivo therapeutic effect was striking when both CD4 and CD8 reactive peptides were delivered to the tumor and all tumors were rejected. Delivery of p876 alone was not effective, indicating the need to recruit and sustain CTL activity in vivo. Treatment with PADRE alone had a minor anti-tumor effect (not shown), but was not nearly as effective as p876 and PADRE together. PADRE can bind to I-A d or I-E d antigen expressed by the professional antigen presenting cells (APC) or non-professional APC like the endothelial cells (Rose, 1997) and activate CD4 T cells. Interaction between activated CD4 T cells and APC can further enhance the antigen presenting capacity of the latter (Bennett et al., 1998; Schoenberger et al., 1998) . Cytokines generated by activated CD4 T cells recruit and activate additional APC, CD8 T cells and non-specific inflammatory cells.
With the proposed scheme, several major obstacles in tumor immunotherapy, namely, tolerance to self-antigens, induction of autoimmunity or the lack of tumor-specific antigens may be circumvented. Because the peptide is foreign, tolerance to the antigen is not an issue. After the peptide treatment is terminated, there is no lingering immune reactivity to self-antigens. Importantly, this therapy does not rely on the expression of tumor-specific antigens because the therapeutic peptides are administered exogenously. Several peptides can be administered simultaneously or sequentially to enhance the therapeutic effect. Each round of peptide treatment represents a booster shot and can increase the frequency of reactive T cells. The observation that 1-day tumor can be eliminated by local delivery of foreign peptides suggests that this strategy may be useful as an adjuvant therapy to eliminate residual tumors at the surgical sites or small tumors not accessible by surgery.
In summary, excellent therapeutic effect was achieved by local delivery of foreign peptides to the tumors. This demonstration provides the basis for developing new strategies to deliver therapeutic foreign peptides to the tumor.
The first synthesis of a prodrug of HLA-A2.1 associated antigenic influenza peptide 2a was accomplished. Two methods for synthesis of prodrugs of antigenic peptides activated by /J-glucuronidase and comprising a self-immolative 3-nitrobenzyloxycarbonyl moiety were investigated. Reaction of 0-glucuronic acid glycoside of 4-hydroxy-3-nitrobenzyl alcohol (3) with iVJV-disuccinimidyl carbonate (DSC) followed by conjugation with AlaOMe, Gly, Thr, PheLeu, and Leu-Arg gave carbamates 4a-4f. Deacetylation of 4b and 4e with MeONa/MeOH gave ö-glucuronides 5b and 5e. Compound 5e was converted to yS-glucuronic acid conjugate 6e by the action of pig liver esterase (PLE). Compound 6e is a substrate for ^-glucuronidase. Method of a direct introduction of the prodrug residue into antigenic nonapeptide GILGFVFTL (2b) failed. Alternately, glycine conjugate 5b was activated to pentafluorophenyl ester 10 Model coupling of 10 with Phe-Leu gave tripeptide conjugate ester 11a which was hydrolyzed by PLE to uronic acid 12. Condensation of 10 with octapeptide ILGFVFTL (9) gave prodrug precursor lib Octapeptide 9 was prepared by de novo synthesis using a racemization-free fragment coupling method. Ester hydrolysis with Ba(OH)a/MeOH gave the target prodrug 2a which is a substrate for 0-glucuronidase. Prodrug 2a does not bind to HLA-A2.1 of T2 human cells defective in major histocompatibility complex I (MHC «-associated peptide processing. Addition of 0-glucuronidase restored the binding to the level observed with parent nonapeptide 2b although higher concentrations of prodrug 2a and enzyme were necessary.
In an effort to design more effective and less toxic drugs against cancer, attention has turned in recent years to prodrugs of antitumor agents. Most of these approaches rely on specific enzymes capable of converting the prodrugs into active species at a tumor site. Selective drug release should reduce the side effects associated with other forms of chemotherapy. This is also the principle of antibody-and gene-directed prodrug therapy (ADEPT 2 -3 and GDEPT 4 ). Prodrugs comprising a carbohydrate moiety amenable to enzyme action attached through a self-immolative benzyloxycarbonyl linker to an anticancer drug (e.g., doxorubicin or daunorubicin, compounds la-lc, Chart 1) have attracted a considerable interest. 5 " 9 The prodrug-activating enzymes include 0-glucuronidase and a-or/3-galactosidase. Prodrug lb (R2 = N0 2 , HMR 1826) activated by^-glucuronidase liberated in necrotic tumors 10 has an increased efficacy and reduced toxicity relative to that of the parent drug. 11 It is a promising candidate for clinical studies. 12 We have reasoned that this prodrug concept can be extended to antigenic oligopeptides 13 (8-10 a.a.) which bind to an extracellular domain of class I major histocompatibility complex (MHC I) or human leukocyte antigen (HLA) and are recognized by CD8 positive cytotoxic T lymphocytes (CTL cell receptor (TCR) and class I HLA/peptide complex on the target cells triggers CTL activity which mediates target cell lysis. 14 The HLA I peptides on tumor cells originate from endogenous proteins but they can be replaced exogenously by synthetic peptides. It has been shown that CTL can kill tumor cells very effectively if the latter were loaded with appropriate peptides. 15 Thus, mice immunized with tumor-associated peptides rejected tumors expressing the specific peptides.
We can then assume that tumors can be rejected if any antigenic peptide which binds to the approriate MHC is delivered to the tumor in an immunized host. Systemic delivery of such antigenic peptide is not possible because it will bind to all nucleated cells resulting in severe toxicity. Effective antitumor activity may be achieved if the peptide is converted to a suitable prodrug which will release the peptide only at the tumor site. Glucuronic acid linked through a benzyloxycarbonyl spacer to the N-terminus of the antigenic peptide seems to fulfill such requirements. The anchor residues at or near the N-and C-termini of peptides are necessary for effective interaction 16 with HLA or MHC I. Blocking one of these sites by a bulky prodrug grouping should eliminate or diminish such a binding. As indicated above for prodrugs la-c, /J-glucuronidase in the microenvironment of tumors can effectively generate an active drug. Substitution at the N-terminus should also reduce the susceptibility of the prodrug toward enzymatic degradation (peptidases) in cell culture and in vivo.
We have chosen a prodrug of nonapeptide GILG-FVFTL (2a) as a target of this study. Parent nona- 
peptide 2b is an influenza matrix peptide 58-66 which was shown to be optimal for binding to HLA-2 and presentation to cytotoxic T lymphocytes. 17 This article deals with the synthesis and biological investigation of peptide prodrug 2a.
Synthesis
Although methods for iV-glycopeptide assembly based on solution-or solid-phase peptide synthesis are available, 18 examples of carbohydrates linked to an Nterminus of a peptide through a spacer are rare. In one instance, a /?-D-galactopyranosyl-( 1-4)-/?-D-glucopyranoside moiety was attached through a butyryl spacer to a neutral tricosapeptide in the last step of solid-phase synthesis. 19 Because nonapeptide 2b is commercially available, a possibility of direct introduction of ß-Dglucuronyl-3-nitrobenzyloxycarbonyl spacer to the Nterminus of 2b was considered first.
Several model experiments were conducted to determine feasibility of such an approach. Reaction of methyl 2,3,4-tri-0-acetyl-/3-D-glucuronyl-3-nitrobenzyl alcohol (3) , iV^V-disuccinimidyl carbonate (DSC), 8 and AlaOMe in the presence of triethylamine gave smoothly compound 4a in 62% yield (Scheme 1). In a similar vein, free amino acids Gly, Phe, and Thr were converted to conjugates 4b-4d in 66-83% yield. Transformation of dipeptides Phe-Leu and Leu-Arg to compounds 4e and 4f in 56 and 41% yield, respectively, was also uneventful. Interestingly, in case of Leu-Arg, attachment of the prodrug moiety occurred at the N-terminus as evidenced by J H NMR spectrum and negative reaction with ninhydrin. This can be explained by a protection of arginine moiety (stronger base than triethylamine) by protonation. 20 Deacetylation 8 of conjugates 4b and 4e with MeONa in MeOH was also problem-free. Compounds 5b and 5e were obtained in 79 and 76% yield, respectively. Methyl glucuronate 5e was hydrolyzed by pig liver esterase (PLE) to give 91% of glucuronic acid derivative 6e. The latter compound was quantitatively digested by/J-glucuronidase from Escherichia coli to give ^-glucuronic acid (7), alcohol 8, and Phe-Leu.
Although these experiments have indicated that a direct introduction of a glucuronyl prodrug residue into N-termini of amino acids or dipeptides is possible, application to nonapeptide 2b was beset with problems from the very beginning. Reaction of 2b with DSC and glucuronyl linker 3 led to formation of a complex mixture of products as shown by HPLC. Although mass spectrum showed that the desired prodrug 2a was also present, preparative separation would be extremely difficult. Therefore, an alternate synthetic approach was devised. Because unprotected carbohydrate moieties interfere neither with the active ester formation nor peptide bond synthesis, 21 » 22 it was anticipated that glycine conjugate 5b can be used for introducing the prodrug function into octapeptide DLGFVFTL (9). As an
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Journal of Medicinal Chemistry, 2002, Vol. 45, No. 4 939 Scheme 3" additional advantage, no deprotection of the glucuronate moiety in the latter stages of prodrug synthesis would be necessary. In a model experiment, conjugate 5b was converted to pentafluorophenyl ester 10 (91%, Scheme 2) which was then reacted with PheLeu to give intermediate 11a in 63% yield. Digestion with PLE gave glucuronic acid conjugate 12 (91%). A similar cleavage of glucuronate prodrugs was described. 23, 24 Compound 12 was readily degraded by j8-glucuronidase from bovine liver to give alcohol 8 and Gly-Phe-Leu.
Next, octapeptide 9 was prepared by a racemizationfree fragment coupling strategy 26 -26 (Scheme 3). Joining of protected amino acid derivatives 13 and 15 gave dipeptide 14 (84%) which was deprotected to give 16 (87%). Coupling with Boc-Phe-OH (18) gave tripeptide 17 (77%). Deprotection afforded tripeptide fragment 19 (82%). In a similar fashion, Boc-Phe-OH (18) was coupled with to furnish dipeptide 21 (81%). Debenzylation led to 22 (90%) which was converted to pentapeptide 23 by condensation with tripeptide 19 (70%). Deprotection then afforded pentapeptide 24 (90%), a key fragment for synthesis of octapeptide 9. Dipeptide 26 was prepared from Gly-OBn (25) and Boc-Leu-OH (27) in 87% yield. Deprotection of 26 gave dipeptide 28 (85%) which was extended to tripeptide 29 (77%) with Boc-De-OH (30). Debenzylation afforded a key tripeptide fragment 31 (85%). Coupling of both fragments 24 and 31 gave octapeptide 32 (66%) which was totally deprotected by hydrogenolysis in AcOH followed by treatment with TFA to give ILGFVFTL (9) in 62% yield.
Condensation of 10 with octapeptide 9 gave the methyl ester of the prodrug lib (36%). In contrast to dipeptide 5e and tripeptide 11a, the nonapeptide ester prodrug lib was a poor substrate for PLE. Therefore, ester lib was hydrolyzed with Ba(OH)2 in MeOH 24 to give target prodrug 2a (37%). Digestion of 2a with ß-glucuronidase from bovine liver gave benzyl alcohol 8 and nonapeptide 2b which were identical with authentic samples.
Biological Studies
Binding of nonapeptide 2b and prodrug 2a to HLA-A2.1 was investigated with T2 human cells defective in MHC I-associated peptide processing. 27 Because of the defect, HLA-A2.1 on these cells do not contain endogenous peptides, are unstable, and promptly degraded, resulting in a low level of HLA-A2.1 on the surface. Binding of exogenous peptides to A2.1 gives stable MHC/peptide complexes and increased level of surface HLA-A2.1 which can be detected by flow cytometry.
Nonapeptide 2b binds to T2 cells in a dose-dependent manner in the range of 15 to 60 /M. At 60 fM of 2b, the HLA-A2.1 level increased to 230% of control cells which were incubated without peptide or ß-glucuronidase at pH 6.5-7.0 to approach the physiological conditions. The enzyme alone did not affect the level of HLA-A2.1 (data not shown). Incubation of nonapeptide prodrug 2a up to the 120 /M level without yS-glucuronidase had no effect on HLA-A2.1, indicating a complete absence of binding (Figure 1 ). In the presence of 200 and 300 units/mL of /?-glucuronidase, HLA-A2.1 level increased with increasing concentration of the enzyme. At 300 units/mL of the enzyme and 120 fM of prodrug 2a, the HLA-A2.1 level increased to 210% of the control value. Therefore, /J-glucuronidase liberated active nonapeptide 2b from prodrug 2b. Although this pH may not be optimal 28 for the activity of/?-glucuronidase in a tumor environment, there is a significant release of active nonapeptide 2b to mark the cells. Further biological investigations are in progress.
Conclusion
We have elaborated two basic strategies for introduction of prodrug grouping, which can be activated by /3-glucuronidase, into amino acids and peptides. This effort culminated in the synthesis of the first prodrug of antigenic nonapeptide GILGFVFTL (compound 2a). Nonapeptide 2b released from 2a by the action of /3-glucuronidase binds to T2 cells in a dose-dependent manner but it is inactive in the absence of the enzyme. This has demonstrated that a prodrug therapy concept previously employed in the context of antitumor anthracycline antibiotics is applicable to exogenous antigenic peptides to mark tumor cells for immune destruction.
